

## Wockhardt launches generic version of anti-convulsant drug Lamictal XR<sup>®</sup>

***Parsippany, NJ, January 8, 2013***

***Mumbai, India, January 8, 2013***

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 25mg, 50mg, 100mg, 200mg and 300mg extended release tablets of Lamotrigine, which is used in treatment of epilepsy. Lamotrigine is the generic name for the brand Lamictal XR<sup>®</sup>, marketed in the United States by Glaxo SmithKline. Wockhardt is launching the product immediately and will be amongst the earliest generic versions of this product in the market.

“We are continuing our rapid momentum of 2012 into the New Year with this approval of Lamotrigine extended release tablets”, said Dr. Habil Khorakiwala, Wockhardt Founder Chairman & Group CEO. “This is the sixth product with drug delivery technology that has received US FDA approval in the last 5 months, a continuing testimony to the R & D capabilities of Wockhardt”, he said.

According to IMS Health, the total market for this product in the US is about \$250 million. Lamotrigine is used extensively in management of epilepsy. Wockhardt already markets several other products in the United States in the CNS segment, especially anti-convulsant drugs.

In the US generic pharmaceutical market, Wockhardt has been consistently growing market shares for all its products. In many instances, Wockhardt, by virtue of being amongst the few players to market technically challenging products has reaped the advantage of being an early entrant.

Wockhardt will be manufacturing the extended-release tablets of Lamotridine at its facility in Aurangabad, India. The technology for the extended release tablets was developed in-house.

### **About Wockhardt:**

Wockhardt is a high-technology intensive global pharmaceutical and biotechnology company with multi-disciplinary and innovative R&D programmes. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 81% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 578 scientists, of whom 80 are doctorates. In all, Wockhardt has 169 Patents granted worldwide. In biotechnology research, it has built a competent ‘Concept to Market’ capabilities in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 7,900 people from 21 different nationalities.

Lamictal XR<sup>®</sup> is a registered trademark of Glaxo SmithKline.